Literature DB >> 18676858

Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo.

Kevin Morgan1, Alan J Stewart, Nicola Miller, Peter Mullen, Morwenna Muir, Michael Dodds, Federico Medda, David Harrison, Simon Langdon, Robert P Millar.   

Abstract

Activation of gonadotropin-releasing hormone (GnRH) receptors inhibits proliferation of transformed cells derived from reproductive tissues and in transfected cell lines. Hence, GnRH receptors represent a therapeutic target for direct action of GnRH analogues on certain proliferating cells. However, more cell biological data are required to develop this particular application of GnRH analogues. Therefore, we compared the effects of GnRH receptor activation in transfected HEK293 cells (HEK293([SCL60])) with transfected human ovarian cancer cell lines SKOV3 and EFO21, human hepatoblastoma HepG2 cells, and rat neuroblastoma B35 cells. Marked differences in receptor levels, magnitude of inositol phosphate generation, and dynamics of inositol phosphate turnover occurred in the different cells. Activation of GnRH receptors, expressed at high or moderate levels, inhibited the growth of HEK293([SCL60]) and B35 cells, respectively. Western blotting detected markers of apoptosis [cleaved poly(ADP-ribose) polymerase, caspase-9] in HEK293([SCL60]) and B35 following treatment with 100 nmol/L d-Trp(6)-GnRH-I. Cell growth inhibition was partially or completely rescued with inhibitor Q-VD-OPh or Ro32-0432. Low levels of GnRH receptor expression in transfected SKOV3, EFO21, or HepG2 activated intracellular signaling but did not induce apoptosis or significantly affect cell proliferation. Tumor xenografts prepared from HEK293([SCL60]) regressed during treatment with d-Trp(6)-GnRH-I and growth of xenografts derived from transfected B35 was slowed. SKOV3 xenografts were not growth inhibited. Therefore, differences in levels of GnRH receptor and signaling differentially affect the apoptotic machinery within cell lines and contribute to the cell type-specific effects of GnRH on growth. Further studies should exploit the growth-inhibitory potential of GnRH receptor activation in abnormal cells in diseased human tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676858     DOI: 10.1158/0008-5472.CAN-08-0197

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides.

Authors:  Daryn Goodwin; Pegah Varamini; Pavla Simerska; Istvan Toth
Journal:  Pharm Res       Date:  2014-11-19       Impact factor: 4.200

2.  Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs.

Authors:  Shayli Varasteh Moradi; Pegah Varamini; Istvan Toth
Journal:  AAPS J       Date:  2015-05-09       Impact factor: 4.009

3.  Pulsatile and sustained gonadotropin-releasing hormone (GnRH) receptor signaling: does the ERK signaling pathway decode GnRH pulse frequency?

Authors:  Stephen P Armstrong; Christopher J Caunt; Robert C Fowkes; Krasimira Tsaneva-Atanasova; Craig A McArdle
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

4.  GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.

Authors:  Cristiana Angelucci; Gina Lama; Fortunata Iacopino; Silvia Ferracuti; Aldo V Bono; Robert P Millar; Gigliola Sica
Journal:  Endocrine       Date:  2009-04-28       Impact factor: 3.633

5.  GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Authors:  Kevin Morgan; Colette Meyer; Nicola Miller; Andrew H Sims; Ilgin Cagnan; Dana Faratian; David J Harrison; Robert P Millar; Simon P Langdon
Journal:  BMC Cancer       Date:  2011-11-03       Impact factor: 4.430

6.  Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity.

Authors:  Peng Xu; Jincan Chen; Zhuo Chen; Shanyong Zhou; Ping Hu; Xueyuan Chen; Mingdong Huang
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

7.  Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent.

Authors:  Kevin Morgan; Samuel P Leighton; Robert P Millar
Journal:  J Mol Biochem       Date:  2012-06-16

8.  Leuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: an atomic force microscopy study of agonist/receptor interaction.

Authors:  Gina Lama; Massimiliano Papi; Cristiana Angelucci; Giuseppe Maulucci; Gigliola Sica; Marco De Spirito
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

9.  Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.

Authors:  Hsien-Ming Wu; Hsin-Shih Wang; Hong-Yuan Huang; Chyong-Huey Lai; Chyi-Long Lee; Yung-Kuei Soong; Peter Ck Leung
Journal:  BMC Cancer       Date:  2013-06-20       Impact factor: 4.430

10.  Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.

Authors:  Colette Meyer; Andrew H Sims; Kevin Morgan; Beth Harrison; Morwenna Muir; Jianing Bai; Dana Faratian; Robert P Millar; Simon P Langdon
Journal:  Endocr Relat Cancer       Date:  2013-02-18       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.